| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 13.11 | 8.73 | 22.65 | 0.59 |
Op profit growth | -2.64 | 56.65 | 5.06 | -4.89 |
EBIT growth | 5.26 | 52.1 | 34.89 | -11.61 |
Net profit growth | 11.83 | -3.67 | 113.98 | -26.72 |
Profitability ratios (%) | ||||
OPM | 17.48 | 20.31 | 14.1 | 16.46 |
EBIT margin | 14.32 | 15.39 | 11 | 10 |
Net profit margin | 10.12 | 10.24 | 11.56 | 6.62 |
RoCE | 14.25 | 15.22 | 10.81 | 8.12 |
RoNW | 2.96 | 2.93 | 3.59 | 1.9 |
RoA | 2.52 | 2.53 | 2.84 | 1.34 |
Per share ratios (₹) | ||||
EPS | 131.16 | 117.28 | 121.9 | 54.96 |
Dividend per share | 30 | 25 | 25 | 20 |
Cash EPS | 61.12 | 43.46 | 51.92 | -7.85 |
Book value per share | 1,154.41 | 1,060.82 | 938.71 | 757.73 |
Valuation ratios | ||||
P/E | 6.56 | 7.7 | 5.11 | 7.57 |
P/CEPS | 14.08 | 20.77 | 12 | -52.99 |
P/B | 0.74 | 0.85 | 0.66 | 0.54 |
EV/EBIDTA | 17.07 | 18.27 | 17.4 | 15.7 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 35.04 |
Tax payout | -29.38 | -32.86 | 7.66 | -32.43 |
Liquidity ratios | ||||
Debtor days | 98.6 | 95.73 | 94.6 | 100.33 |
Inventory days | 81.56 | 77.1 | 66.84 | 73.63 |
Creditor days | -48.75 | -46.38 | -39.69 | -45.1 |
Leverage ratios | ||||
Interest coverage | -32.22 | -30.23 | -19.61 | -18.13 |
Net debt / equity | 0.05 | 0.05 | 0.12 | 0.38 |
Net debt / op. profit | 0.25 | 0.24 | 0.81 | 2.04 |
Cost breakup (₹) | ||||
Material costs | -34.54 | -31.91 | -31.7 | -28.28 |
Employee costs | -18.03 | -19.05 | -19.29 | -22.51 |
Other costs | -29.93 | -28.71 | -34.89 | -32.73 |
Issuance of a Form 483 occurs when an investigator(s) has observed any conditions that in their judgment may constitute violations of the FD&C Act and related Acts.
The board has recommended a final dividend of ₹8 per equity share for FY 2024–25
Here are some of the stocks that may see significant price movement today: Adani Power, Dr Reddy's, and Bank of India, etc.
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.
Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore.
The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.
Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
